Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Liquid Biopsy
OraSure, nRichDx to offer products for researchers developing urine-based liquid biopsy assays
The firms noted that their products use first-void urine, which is enriched in biomarkers suitable for molecular analysis by people researching sexually-transmitted infections, human papillomavirus, and early stage cancers.
March 27, 2023
Guardant Health, Ohio State University study colorectal cancer screening adherence
The Ohio State University-led study will evaluate changes in CRC screening adherence in underserved urban and rural communities. Guardant Health is providing its Shield blood test to eligible individuals through mobile health clinic partners.
March 21, 2023
Natera receives commercial payor coverage for molecular residual disease test
Among the first commercial coverage policies for the test, Blue Shield of California began providing coverage of Signatera for plan members diagnosed with solid tumors.
March 2, 2023
UnitedHealthcare increases coverage for Guardant360 CDx liquid biopsy test
The new policy coverage by UnitedHealthcare is in addition to coverage for the liquid biopsy CDx test under UHC Medicare Advantage policies for comprehensive genomic profiling of all solid tumors.
February 8, 2023
Geneseeq nabs CE Marks for minimal residual disease, early cancer detection tests
The firm has received CE Marks for liquid biopsy multicancer minimal residual disease detection and multicancer early detection kits to detect patients with solid tumors.
January 24, 2023
Agilent, Quest extend access to NGS liquid biopsy CDx for NSCLC
The agreement between Agilent and Quest aims to enable broader adoption of ctDx First, a single-site premarket approved test performed at the Resolution Bioscience CLIA-certified laboratory in Kirkland, WA.
January 23, 2023
Most Popular
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
Quest Diagnostics offers suite of services for transplant patients and living donors
Simple blood test can detect PTSD biomarkers
Rapid nirmatrelvir treatment in study reduced long-COVID risk
Illumina NGS software to enable tertiary analysis for oncology, rare disease
Serum protein in study predicted which patients might die without a liver transplant
$1.3 billion liquid biopsy market represents the present and future of clinical oncology: Kalorama
The liquid biopsy market can be segmented by the type of analyte detected and analyzed. There are four main categories: circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes and other analytes, and multiple analytes.
January 19, 2023
FoundationOne Liquid CDx receives FDA approval for use with Rozlytrek (entrectinib)
The CDx is indicated for use with patients who do not have a tissue sample available and may be appropriate for treatment with Rozlytrek (entrectinib), a targeted therapy developed by Genentech.
January 4, 2023
Aptorum Group announces publication on metagenomics sequencing workflow on Illumina platforms
The paper, entitled “Towards a rapid-turnaround low-depth unbiased metagenomics sequencing workflow on the Illumina platforms,” is available as a preprint on medRxiv.
January 4, 2023
Datar Cancer Genetics obtains FDA breakthrough device designation for blood test to detect inaccessible brain tumors
A prospective, blinded study by London’s Imperial College researchers showed the TriNetra-Glio liquid biopsy test, which requires 15 mL of blood, can detect malignant brain tumors.
January 3, 2023
Burning Rock nabs FDA breakthrough device designation for multicancer detection blood test
The test, called OverC MCDBT, is intended for early detection of esophageal, liver, lung, ovarian, and pancreatic cancers in adults of either sex from 50 to 75 years of age and at average risk for cancer.
January 3, 2023
Natera supports guideline proposing donor-derived cfDNA testing for heart transplant surveillance
The International Society for Heart and Lung Transplantation proposes monitoring for rejection with noninvasive biomarkers or biopsy monthly during the first six months post-transplant, as well as testing in the ninth and 12th months post-transplant.
December 23, 2022
Page 1 of 3
Next Page
